gefitinib
survival

prognosis

prognostic

clinical

outcome

kinase

therapy

recurrence

OS

disease-free

resistance

recurrence-free

phase II

associated

treatment

targets

Gleason

benefit

phase II

median

patients

ci

trial

disease

overall

effect

relapse-free

trastuzumab

PFS

drugs

response

female

year

factor

level

associate

oral

advance

review

capecitabine

cholangiocarcinoma

grading

develop

inhibitor

existing
receive

therapeutical

month